{
  "id": "breast-biomarker-by-provider",
  "display_name": "Breast Cancer Biomarker Testing by Provider",
  "cohort": "Breast Cancer Biomarker Testing, by Provider (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "Provider variation in breast cancer biomarker testing: Dr. Martinez tests 97% of standard markers, but emerging biomarkers like PIK3CA and BRCA1/2 show lower adoption across providers.",
  "chart": {
    "type": "bar",
    "unit": "provider",
    "data": [
      { "name": "Dr. Martinez", "value": 97, "gap": 12, "highlight": false },
      { "name": "Dr. Johnson", "value": 94, "gap": 9, "highlight": false },
      { "name": "Dr. Lee", "value": 92, "gap": 7, "highlight": false },
      { "name": "Dr. Chen", "value": 85, "gap": 0, "highlight": false },
      { "name": "Dr. Smith", "value": 82, "gap": -3, "highlight": false },
      { "name": "Dr. Williams", "value": 76, "gap": -9, "highlight": true },
      { "name": "Dr. Rodriguez", "value": 78, "gap": -7, "highlight": true }
    ],
    "benchmark": 85,
    "nccn_target": 95
  },
  "financial_impact": {
    "annual_opportunity": "$165,000/year",
    "math": "$165,000/year = 8% testing gap (lagging providers) × 75 breast cancer patients × $27,500 precision therapy value"
  },
  "clinical_impact": {
    "description": "Standardizing breast cancer biomarker testing across providers improves therapy selection and outcomes.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+5.8 months",
        "description": "Improved progression-free survival with matched therapies"
      },
      {
        "type": "OS",
        "value": "+7.3 months",
        "description": "Overall survival benefit with biomarker-guided treatment"
      },
      {
        "type": "ORR",
        "value": "+32%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "QoL",
        "value": "+26%",
        "description": "Improved quality of life scores"
      },
      {
        "type": "TTF",
        "value": "-38%",
        "description": "Reduced time to treatment failure"
      }
    ],
    "quantitative": "+7.3 months OS"
  },
  "peer_comparison": {
    "description": "Leading breast oncologists achieve >95% comprehensive biomarker testing rates, particularly with expanded molecular testing.",
    "peer_benchmark": 95,
    "financial_impact": {
      "annual_opportunity": "$210,000/year",
      "math": "$210,000/year = $165,000 direct therapy value + $45,000 clinical trial enrollment"
    },
    "action_steps": [
      {
        "text": "Standardize expanded biomarker protocols across all providers",
        "icon": "document"
      },
      {
        "text": "Create provider-specific performance dashboards",
        "icon": "chart"
      },
      {
        "text": "Develop PIK3CA testing pathway for all HR+ metastatic cases",
        "icon": "cog"
      },
      {
        "text": "Establish automated BRCA1/2 testing triggers",
        "icon": "bell"
      }
    ]
  },
  "weighted_score": 89,
  "action_steps": [
    {
      "text": "Implement standardized PIK3CA testing protocol for HR+/HER2-",
      "icon": "document"
    },
    {
      "text": "Create provider-specific biomarker compliance dashboard",
      "icon": "chart"
    },
    {
      "text": "Schedule provider education on emerging breast biomarkers",
      "icon": "calendar"
    },
    {
      "text": "Develop EMR-based expanded biomarker testing alert",
      "icon": "bell"
    }
  ],
  "suggestions": [
    {
      "text": "Analyze patient demographics by provider",
      "icon": "search"
    },
    {
      "text": "Evaluate provider understanding of PIK3CA clinical utility",
      "icon": "clipboard"
    }
  ],
  "drilldowns": [
    {
      "label": "By Testing Method",
      "cohort": "Breast Cancer Testing by Method",
      "jsonFile": "breast-biomarker-by-method.json",
      "drilldownLevel": 3
    },
    {
      "label": "All Breast Biomarkers",
      "cohort": "Breast Cancer Biomarker Testing",
      "jsonFile": "breast-biomarker.json",
      "drilldownLevel": 2
    },
    {
      "label": "All Providers",
      "cohort": "Biomarker Testing by Provider",
      "jsonFile": "biomarker-compliance-by-provider.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 